CRITICAL INNOVATIONS LLC — Department of Defense SBIR Phase II: CBD212-005

CRITICAL INNOVATIONS LLC — SBIR Phase II award from Department of Defense.

Amount
$275,581
Agency
Department of Defense · Office for Chemical and Biological Defense
Program / Phase
SBIR · Phase II
Topic
CBD212-005
Solicitation
21.2
NAICS
Place of performance
CA
Period
2023-06-23 → 2025-07-02

Description

The Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical (JPM CBRN Medical) seeks to develop dermal dressing technologies that provide multiple advantages over current wound dressings for treating dermal injuries caused by sulfur mustard. Critical Innovations, Battelle's Biomedical Research Center, the U.S. Army Combat Capabilities Development Command Chemical Biological Center (DEVCOM CBC), and NDA Partners, with consultants Captain David Tanen, MD, FAAEM, FACMT (USN, Ret.) and Dr. Christopher Burns, MD, FACS, have formed a team of medical device experts to address this important medical need. During this Phase II project, our objectives will be to further advance the innovative Succor product. This will include: 1) On-boarding program-specific requirements, goals, and schedule; 2) Producing a pilot run of cGMP production-equivalent devices for use in program testing; 3) Demonstrating product stability, ruggedness, and readiness for the combat environment; 4) Performing a GLP live-animal study of Succor for Sulfur Mustard; and, 5) Maintaining all program-specific regulatory compliance requirements while preparing for upcoming regulatory and transition hurdles.